Allergan tries to escape Restasis IPRs

Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit orders stay of PTAB’s Restasis proceedings

29 March 2018 The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.

Americas

Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

19 January 2018 Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).

Americas

PTAB dismisses Native American tribe information request

8 January 2018 The Patent Trial and Appeal Board has denied an information request by a Native American tribe, deeming it improper for a number of reasons.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Allergan tries to escape Restasis IPRs

More on this story

Editor's picks

Editor's picks

More features